S
everal Bordetella species have been associated with respiratory disease in humans. Although B. avium is thought to be strictly an animal pathogen that causes tracheobronchitis in wild and domesticated birds (1, 2) , infections in birds share many of the clinical and histopathologic features of disease in mammals caused by B. pertussis and B. bronchiseptica (3) . Human cases of respiratory disease associated with B. avium have only recently been reported in patients with cystic fi brosis (4). We describe 2 isolates, B. avium and a novel strain resembling B. avium, isolated from 2 patients with pneumonia, thereby demonstrating that B. avium and B. avium-like organisms are opportunistic human pathogens.
The Cases
Patient 1, a 68-year-old man with left lower lobe pneumonia and hemoptysis, sought care at a community hospital. The patient had a history of end-stage renal disease requiring hemodialysis, chronic obstructive pulmonary disease (COPD), long-term tobacco use, and ischemic cardiomyopathy being treated with anticoagulation. He had a 10-day history of increasing shortness of breath and cough associated with mild hemoptysis. The initial chest radiograph demonstrated an extensive left-sided infi ltrate, which progressively worsened; the patient ultimately required endotracheal intubation and mechanical ventilation. Bronchoscopy showed purulent secretions in the left mainstem bronchus, complete obstruction of the bronchus, and frothy secretions in the right airways. Gram-stained bronchoalveolar lavage (BAL) fl uid showed many polymorphonuclear leukocytes but no organisms. Routine bacterial culture of the fl uid isolated a pure culture that was phenotypically identifi ed by API NFT rapid test strip (bioMérieux, Hazelwood, MO, USA) as B. avium. Antimicrobial drug-susceptibility testing performed using Etest (AB Biodisk, Solna, Sweden) resulted in the following MICs: ceftriaxone 2 μg/ mL, azithromycin 4 μg/mL, piperacillin/tazobactam 0.125/4 μg/mL. The patient was initially treated with azithromycin and ceftriaxone and completed empiric therapy with piperacillin/tazobactam and vancomycin. By day 7, the patient's respiratory status improved enough that he could be extubated. Follow-up chest radiographs showed substantial resolution of the left-sided infi ltrates, and on day 11, the patient was discharged to a rehabilitation care facility.
Patient 2, a 61-year-old homeless man, was admitted to the Houston DeBakey Veteran Affairs Medical Center with a 4-month history of productive cough and a 1-month history of sporadic hemoptysis. He denied fever, chills, shortness of breath, and chest pain. His medical history included COPD, pulmonary tuberculosis, and long-term use of tobacco and alcohol. HIV ELISA result was negative. Chest radiographs and computed tomography scan showed marked emphysematous changes with bullae in the posterior left lobe, numerous calcifi ed granulomas compatible with old granulomatous disease in the left lung, and pleural thickening and reaction in the left apex. A lobulated 2-cm soft tissue density in 1 of these cavities was also identifi ed. No acute infi ltrates were seen. The patient began treatment for COPD and for suspected pulmonary tuberculosis (ethambutol 1,600 mg/day, rifampicin 600 mg/day, pirazinamide 1,500 mg/day, and isoniazid 300 mg/day). Gram-stained BAL fl uid showed many polymorphonuclear leukocytes and small gram-negative rods. Routine bacterial culture of BAL fl uid isolated a pure culture that was identifi ed as Bordetella spp. but that could not be identifi ed to the species level by API NFT rapid test strip. Susceptibility testing was performed by using the Kirby-Bauer diskdiffusion method. Although no susceptibility guidelines for Bordetella spp. have been established, the isolate appeared to be sensitive to amikacin, trimethoprim-sulfamethoxazole, gentamicin, ceftazidime, and imipenem and resistant to ampicillin, ampicillin/sulbactam, and aztreonam. An oral cephalosporin drug was added to the patient's regimen. Three sputum samples were negative for acid-fast bacilli, and treatment for tuberculosis was discontinued. The patient was discharged 9 days after hospital admission.
Isolates of nonlactose fermenting, small, gram-negative rods were recovered from BAL fl uid by using trypticase soy agar supplemented with 5% sheep blood, chocolate agar, and MacConkey agar incubated at 35°C in 5% CO 2 . The isolate from patient 1 was phenotypically consistent with B. avium (catalase positive, oxidase positive, nitrate reduction negative, urease negative). The isolate from patient 2 was phenotypically inconsistent with all other well-characterized Bordetella spp. (catalase positive, oxidase positive, nitrate reduction positive, urease negative) and could not be phenotypically identifi ed to the species level.
Sequence analysis was performed by PCR targeting the 16S rRNA gene as previously described (5) . Samples were prepared by using the ABI PRISM BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA), and sequencing reactions were performed by using the ABI PRISM 3100 Analyzer according to manufacturer's instructions. Sequences were aligned by using Sequencher software and were submitted to GenBank BLAST database. The sequence from patient 1 was genetically identical to B. avium type strain ATCC 35086 (477 bp evaluated, 100% sequence similarity), and the sequence from patient 2 was related to B. avium type strain ATCC 35086 (509 bp evaluated, 98% sequence similarity [submitted as GenBank accession no. EU352642]). Several 16S rRNA gene sequences of type strains from the genus Bordetella were retrieved from GenBank, and a phylogenetic tree was constructed by using a neighbor-joining algorithm with Achromobacter xylosoxidans xylosoxidans as the outgroup (Figure) . Concise alignment of the sequence from patient 2 showed 11-bp and 15-bp differences compared with B. avium (type strain ATCC 35086) and B. trematum (type strain DSM 11334), respectively. Thus, it represents a novel uncharacterized strain most closely related to B. avium (i.e., B. avium-like; Figure) . Both the genotype of B. avium and the novel strain are distinguishable from other Bordetella spp. according to 16S rRNA gene sequencing of the fi rst 500 bp (≈2% bp difference). This fi nding is in contrast to the indistinguishable sequences of B. pertussis, B. parapertussis, B. bronchiseptica, and the closely related B. homlseii, which can be a limitation of 16S rRNA gene sequencing for the genus Bordetella, particularly when only the fi rst 500 bp are evaluated (Figure) .
Conclusions
Although the fi rst report of human disease associated with B. avium was recently described in patients with cystic fi brosis (4), the role of B. avium in respiratory infection as opposed to colonization in patients with cystic fi brosis is unclear. The cases in this report provide a more direct clinical association of human respiratory infection and B. avium and B. avium-like organisms. Each of the 2 isolates was obtained in pure culture from BAL fl uid. Although neither patient was conventionally immunocompromised (e.g., no HIV, hematologic disorders, or immunosuppressive therapy), each was an older person who had underlying pulmonary problems along with other medical conditions, and each belonged to a patient population typically susceptible to opportunistic infections. Each patient had signs and symptoms clinically consistent with respiratory syndromes caused by Bordetella, and each responded to treatment. Clinicians should be aware that human infections with B. avium may pose some antimicrobial drug treatment challenges. A previous report demonstrated that cultures of B. avium were consistently resistant to penicillin and cefuroxime but susceptible to mezlocillin, piperacillin, gentamicin, amikacin, and cefoperazone (6) . Although B. avium has been shown to share several virulence factors with B. pertussis, B. parapertussis, and B. bronchiseptica, it does not carry genes that encode pertussis toxin or adenylate cyclase toxin (7) . B. avium and B. avium-like organisms have yet-unidentifi ed virulence factors, which may contribute to their ability to cross over from an animal host to an opportunistic human pathogen.
Dr Harrington is laboratory director for methicillin-resistant 
